Latest News

Nebius' growth projections place it on a different level.

Altimmune (NASDAQ:ALT) executives said the company is preparing to begin enrolling patients in the second half of the year for a Phase 3 trial of pemvidutide in metabolic dysfunction-associated steatohepatitis, or MASH, while also awaiting data from related alcohol-associated liver disease programs.

While much of the chip sector dropped sharply, the software and cloud giant barely budged -- and its diversified path to AI revenue may be the reason.

The e-commerce and cloud giant's record spending is funding a fast-growing chip business that investors arguably aren't giving enough credit.

This advanced materials supplier to high-growth sectors just reported a notable insider sale, according to recent SEC filings.

This home services and insurance software firm reported a notable insider sale as part of its ongoing executive selling cadence.

IntroductionFinding a home that combines affordability, comfort, and connectivity is a priority for many homebuyers in the Delhi NCR region. Over the last

These are both highly profitable and have several revenue streams.

This clinical-stage biotech focused on inflammatory diseases reported a notable insider sale amid a year of sharp share price declines.

Align Technology (NASDAQ:ALGN) CFO John Morici said the company continues to navigate a challenging but stable demand environment, with international markets and dental service organizations offsetting pressure in parts of North America. Speaking at the Jefferies Global Healthcare Conference in a f

Both of these chip giants are central to the AI build-out, but one looks like the better buy today.

This technology-driven insurer, focused on residential markets, reported significant insider selling in its latest SEC filing.

Ford took a $19.5 billion noncash charge just months ago and has turned that into a big triumph with its new venture.

Aldeyra Therapeutics (NASDAQ:ALDX) Chief Executive Todd Brady said the company expects near-term feedback from the U.S. Food and Drug Administration on its dry eye disease candidate reproxalap, following a third complete response letter tied to efficacy questions. Speaking at a Jefferies fireside c

The space sector is lifting off as SpaceX approaches its IPO.

Alphabet is signaling continues investments in AI.

Sales are booming as consumers flock to places that offer value.

Nvidia continues to deliver excellent financial performance, while the stock price increases only modestly.

As businesses grow, their customer relationship management requirements become more complex. Organizations need advanced tools that can support sales growt

Some investors fear that Broadcom stock has peaked. That could be a costly mistake.

Rubrik soared last month, but not entirely on its own merits. Here's the real story behind the surge.

S&P Dow Jones is considering altering its index admission policy to fast-track their entries.

Modern businesses operate in an environment where sales cycles are faster, customer expectations are higher, and competition is more intense than ever befo

Joby Aviation is becoming a leader in the eVTOL industry.

Akebia Therapeutics (NASDAQ:AKBA) outlined its commercial priorities for Vafseo, the expected evolution of reimbursement after the TDAPA period and several renal-disease pipeline programs during a fireside chat at the Jefferies 2026 Global Healthcare Conference. Erik, Akebia’s chief financial offic